Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
X. Cynthia, Matthew J. Ellis(University of California, Davis), Charles Erlichman(Roswell Park Comprehensive Cancer Center), Timothy Pluard(Southwestern Medical Center), Robert G. Crowder(Knoxville College), César Sánchez(Pontificia Universidad Católica de Chile), Allison Creekmore, Feng Gao(Hebei Medical University), Michael Naughton(Boston College), A. Craig Lockhart(Roswell Park Comprehensive Cancer Center), A. E. Doyle, Zhanfang Guo(Washington University in St. Louis), Jeremy Hoog(Washington University in St. Louis)
Cited by 0
Related Papers
A tutorial review of economic model predictive control methods
|Journal of Process Control|2014|711
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663